NEWAMSTERDAM PHARMA CO N.V.
NEWAMSTERDAM PHARMA CO N.V. (NAMS): 9 pipeline candidates · 5 upcoming catalysts · ~62 mo cash runway · 8 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
62.1 months
D/E 0.10 · 4% dilution
Lead: Phase 3
9 candidates
5 upcoming, next in ~593d
0 buys · 35 sells (180d)
A transparent, data-derived signal for NEWAMSTERDAM PHARMA CO N.V.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.5B
Cash
$457.6M
Quarterly Burn
$30.6M
Runway
62.1 mo
Revenue
$3.0M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| atorvastatin | Phase 1 |
| monotherapy ezetimibe | Phase 3 |
| monotherapy obicetrapib | Phase 3 |
| obicetrapib | Phase 3 |
| obicetrapib + ezetimibe | Phase 3 |
| obicetrapib + ezetimibe fdc | Phase 3 |
| obicetrapib 10 mg + ezetimibe 10 mg fdc daily | Phase 3 |
| obicetrapib 10 mg + obicetrapib/evolocumab 140 mg q 2 weeks | Phase 3 |
| rosuvastatin | Phase 1 |
Upcoming Catalysts (5)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
167
Total value held
$2.82B
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 9,550,191 | $305.7M |
| fcpm iii services b.v. | 9,198,900 | $294.5M |
| fmr llc | 8,765,811 | $280.6M |
| wellington management group llp | 5,115,818 | $163.8M |
| janus henderson group plc | 4,517,968 | $144.5M |
| deerfield management company, l.p. | 4,264,789 | $136.5M |
| viking global investors lp | 4,203,567 | $134.6M |
| polar capital holdings plc | 2,831,607 | $90.6M |
| jennison associates llc | 2,750,403 | $88.0M |
| medicxi ventures management (jersey) ltd | 2,674,182 | $85.6M |
Showing top 10 of 167 institutional holders of NEWAMSTERDAM PHARMA CO N.V.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in NEWAMSTERDAM PHARMA CO N.V.'s pipeline?
NEWAMSTERDAM PHARMA CO N.V. (NAMS) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is NEWAMSTERDAM PHARMA CO N.V.'s lead drug candidate?
NEWAMSTERDAM PHARMA CO N.V.'s most advanced tracked candidate is atorvastatin (Phase 1) for Healthy Volunteers.
What is NEWAMSTERDAM PHARMA CO N.V.'s next catalyst?
NEWAMSTERDAM PHARMA CO N.V.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Placebo-controlled, Double-blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib/" — expected February 1, 2028.
What is NEWAMSTERDAM PHARMA CO N.V.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, NEWAMSTERDAM PHARMA CO N.V. has approximately 62.1 months of cash runway.
What is NEWAMSTERDAM PHARMA CO N.V.'s market capitalization?
NEWAMSTERDAM PHARMA CO N.V.'s market capitalization is approximately $3.5B.
Get the full picture on NEWAMSTERDAM PHARMA CO N.V.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.